Published in Cancer Weekly, August 31st, 2004
Adjusting for the previously announced 2-for-1 stock split that will take effect this July 30, net earnings for the third quarter were $0.30 per diluted share, up 30 percent from $0.23 per diluted share recorded in the third quarter of last fiscal year.
The company reported third quarter sales of $303 million, up 14% versus the year-ago quarter. Net orders for the third quarter were $328 million, up 15% from the year-ago period. Backlog at the end of the third quarter stood at $903...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.